NR1H4 and metabolic dysfunction-associated steatohepatitis: In patients with NASH, nonbile acid–derived FXR agonists EDP-305 and tropifexor (which is also a nonsteroidal FXR agonist) were also associated with pruritus as the most commonly reported adverse event, suggesting that this is a class effect [48,49].